Diabetes

The SURPASS program, which consists in part of SURPASS-3 and SURPASS-5, is testing the efficacy and safety of tirzepatide, a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.

Prediabetes may not be a robust diagnostic biomarker for predicting future diabetes development in older adults.

Results of a prospective cohort study suggest history of gestational diabetes (GD) may promote development of atherosclerotic plaque, potentially increasing the risk of future heart disease among women, even in the absence of hyperglycemia.

There needs to be broad acceptance of the role systemic racism plays in social determinants of health in order to improve metabolic outcomes among minority populations in the United States.

A prospective cohort study found that diabetes and insulin resistance were the strongest risk factors for premature onset of coronary heart disease (CHD) among American women. Results were published in JAMA Cardiology.

Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes (T2D), according to results of a 10-year follow-up study of a randomized controlled trial published in The Lancet.

Results of a vignette-based survey study indicate patients with diabetes require greater health benefits to adopt more intrusive remote digital monitoring (RDM), food monitoring, and real-time feedback by a health care professional.

Results of a phase 2 trial showed that an activin type II receptor blockade, achieved via bimagrumab, led to significant loss of fat mass, gain in lean mass, and metabolic improvements among patients with type 2 diabetes (T2D) and overweight or obesity.

Non-Hispanic Black individuals with type 1 diabetes and coronavirus disease 2019 infections may be more likely to be hospitalized for diabetic ketoacidosis (DKA) compared with non-Hispanic White patients.

A new American Diabetes Association (ADA) survey highlights how the coronavirus disease 2019 (COVID-19) pandemic took a toll on the population with diabetes, which is one of the most prevalent preexisting conditions in America.

The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.

Michael Snyder, PhD, professor and chair of genetics at the Stanford University School of Medicine, discusses the ways in which precision health measurements can aid physicians in detecting and better managing diabetes.

A reduction in glycated hemoglobin (A1C) may result in improved perinatal and maternal outcomes among women with prepregnancy diabetes, according to results of a cohort study published in JAMA Network Open.

Using advanced machine learning models, researchers in China were able to accurately predict incidence of gestational diabetes among pregnant women during their first trimester.

Advancements in coverage for diabetes technology and improvement in diabetic retinopathy screening rates appear on this year’s list of most-read diabetes articles.

The identification and assessment of frailty, defined as a state of increased vulnerability to adverse health outcomes resulting from loss of physiological reserve, should become a routine aspect of diabetes care, authors of a systematic review and meta-analysis published in The Lancet Health Longevity argued.

An outcomes-based agreement conducted by Boehringer Ingelheim and Highmark found that use of Jardiance (empagliflozin) among adults with type 2 diabetes (T2D) and known cardiovascular disease (CVD) was associated with a total cost of care savings of over 20%.

Results from a phase 2 trial show PXL770 yielded consistently greater responses in high-risk patients with comorbid nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D) compared with placebo.

During a session at the at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts outlined the benefits and limitations of pharmacological, surgical, and lifestyle interventions for pediatric patients with obesity.

In a session at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts discussed challenges faced by patients with diabetes in the wake of the coronavirus disease 2019 (COVID-19) pandemic and lessons learned from the crisis.

Large telemedicine diabetic retinopathy screening networks based in federally designated safety-net clinics may be able to increase screening access and compliance among otherwise underscreened populations.

For individuals currently in high-risk glycemic categories, losing 2 to 3 kg (4.5-6.5 lb) in combination with increased physical activity over 2 years nearly halved the risk of developing type 2 diabetes (T2D).

Half of patients with type 2 diabetes (T2D) exhibit very high cardiovascular risk while the majority are at a high risk of fatal heart attack or stroke, according to new research published in the European Journal of Preventive Cardiology.

Lowering the higher rates of diabetes seen among racial and ethnic minorities requires solutions to address all of the major factors that contribute to diabetes prevalence.

Black individuals with diabetic macular edema (DME) exhibited a significantly lower likelihood of visual acuity improvement following intravitreal bevacizumab treatment compared with White and Hispanic patients.

New data show combining glucagon-like peptide-1 receptor agonist (GLP-1 RA) exenatide plus sodium–glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin remains effective after 2 years for type 2 diabetes (T2D) uncontrolled with metformin.

A decision was upheld that Johnson & Johnson (J&J) must pay a $2.1-billion fine from a 2018 court decision; 3 major drug distributors face up to $18 billion in opioid-related fines; a new diabetes prevention platform may assist in symptom prevention.

Diabetes and multiple chronic conditions increase overall Medicare spending, but spending increases even more in minority beneficiaries compared with White beneficiaries with similar comorbidity combinations.

This week, CMS proposed changes to the Medicare Durable Medical Equipment Prosthetics, Orthic Devices and Supplies (DMEPOS) coverage and payment policies which would expand Medicare coverage for continuous glucose monitors (CGMs).